M

Moderna

Develops mRNA-based medicines for health

Power Platform & AI Engineer

Full-TimeUpdated on 10/23/2026
$109.2k - $174.6k+ Annual discretionary bonus + Other incentive compensation + Equity award
Senior
Cambridge, MA, USA
Hybrid70% in-office under the stated 70/30 work model.
Software EngineeringAI Application Engineering
No H1B Sponsorship

About the job

Requirements
  • At least 5 years of demonstrated experience as a Microsoft Power Platform administrator and hands-on developer in an enterprise environment.
  • Deep expertise in Microsoft Power Platform, including Power Apps, Power Automate, and Copilot Studio.
  • Experience designing and developing enterprise-grade Power Apps, including Canvas Apps and/or Model-Driven Apps.
  • Experience designing end-to-end Power Platform solutions combining Power Apps, Power Automate, Copilot Studio, Microsoft 365, Dataverse, APIs, and enterprise systems.
  • Experience designing and delivering AI-driven automation solutions.
  • Experience integrating with enterprise systems via APIs or MCP servers.
  • Strong troubleshooting skills and ability to support production-grade AI and automations.
Responsibilities
  • Support administration of Power Platform across development, validation, and production environments.
  • Support implementation and maintenance of the Power Platform Center of Excellence governance framework, including environment strategy and lifecycle management; Data Loss Prevention policies and connector governance; and security roles, licensing, and access controls.
  • Apply and support platform guardrails to ensure solutions are secure, compliant, scalable, and supportable.
  • Manage solution lifecycle, including promotion, versioning, and change management.
  • Partner with Security, Compliance, and Enterprise Architecture to ensure adherence to enterprise standards.
  • Maintain the platform in a GxP-qualified state, ensuring compliance with validation requirements in regulated environments.
  • Maintain system documentation and support updates as platform capabilities evolve, including the System Administration SOP, Use and Operation SOP, and Configuration/Design Specifications.
  • Ensure all changes follow appropriate validation, documentation, and audit readiness processes.
  • Design, develop, and support AI-first automation solutions using Power Apps, Power Automate, and Copilot Studio.
  • Contribute to solution design decisions and recommend appropriate use of Power Apps, Power Automate, Copilot Studio, or hybrid approaches.
  • Develop production-grade Power Apps applications, including Canvas and Model-Driven Apps; Power Automate workflows and process automations; and Copilot Studio agents and conversational experiences.
  • Lead prompt engineering and conversational design, including topics, triggers, and escalation paths.
  • Partner with business stakeholders to identify and implement AI-driven automation opportunities.
  • Integrate solutions with Microsoft 365 and enterprise platforms such as ServiceNow, Jira, and APIs.
  • Contribute reusable patterns, templates, and components to support scalable development.
  • Ensure operational excellence with logging, monitoring, alerting, and exception handling.
  • Evaluate when to extend solutions with robotic process automation technologies such as UiPath.
  • Support enterprise-wide adoption of Power Platform.
  • Contribute to adoption metrics and reporting, including active makers, automation usage, and business value delivered.
  • Develop and deliver structured training programs, workshops, and onboarding pathways.
  • Participate in Community of Practice activities and knowledge-sharing initiatives.
  • Support office hours and hands-on advisory sessions for makers.
  • Provide architecture guidance, design reviews, and production readiness reviews.
  • Provide guidance and support to citizen developers and business users on secure, scalable patterns.
  • Enable a federated development model with strong central governance.
  • Monitor platform health, performance, usage, and failures across AI and automations.
  • Build dashboards using Power Platform analytics and Power BI to track adoption and engagement, operational risk and failures, and business impact.
  • Contribute to continuous improvement of governance, tooling, and development standards.
  • Stay current on the Microsoft roadmap and new platform capabilities and share recommendations with the team.
Desired Qualifications
  • Experience with UiPath development and/or administration.
  • Experience in regulated environments such as pharma, healthcare, GxP, or SOX.
  • Experience with scripting in PowerShell or Python to complement automation workflows.
  • Power Platform certifications such as PL-400, PL-500, PL-600, PL-200, PL-100, or Copilot Studio-related certifications.
  • Strong communication skills and comfort working within a centralized Center of Excellence supporting distributed teams.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 23rd, 2026
Moderna sees $114.9M in net ETF buying as CGGO adds $121.1M stake

ETFs bought $114.9 million of Moderna stock on Wednesday, October 21, ending a one-day net selling streak. Twenty ETFs were buyers and 10 were sellers. CGGO led with 492,604 shares worth $121.1 million, a 1.06% portfolio weight. IBB added $2.0 million and QQQM $1.0 million. The flows followed a $7.5 million net outflow on October 20 and a $26.1 million net inflow on October 19. Over the last five reported days, ETFs were net buyers on three and net sellers on two. Moderna has a market cap of $80.9 billion. Its trailing 12-month revenue was $2.23 billion, down 27.3% over one year, and the shares have returned 587.11% so far this year.

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.